<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437800</url>
  </required_header>
  <id_info>
    <org_study_id>GLMT12-SIL</org_study_id>
    <nct_id>NCT01437800</nct_id>
  </id_info>
  <brief_title>BIOAVAILABILITY OF GLI/METXR (4/850 mg)</brief_title>
  <acronym>GLMT12-SIL</acronym>
  <official_title>Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
      The purpose of this study is to evaluate the oral bioavailability of the combination&#xD;
      Glimepiride/ extended release Metformin (GLI/METXR) (4/850mg) in healthy Mexican volunteers&#xD;
      in fasting conditions.&#xD;
&#xD;
      Methods: A prospective, longitudinal, open label, non randomized study, was performed, 24&#xD;
      volunteers were administrated with a single oral dose of GLI/METXR (4/850 mg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples were collected over 30 hours. Plasma concentration of both drugs were measured&#xD;
      by using high-performance liquid chromatography (HPLC). Plasma concentration-time curves were&#xD;
      plotted for each volunteer, and pharmacokinetic parameters (PK) were calculated. the&#xD;
      pharmacokinetic parameters to be determined are: Cmax, Tmax, AUC0-t, AUC0-inf, TMR, Ke, T1 /&#xD;
      2 of glimepiride and metformin Adverse events were determined using clinical and laboratory&#xD;
      test results, throughout the study. The statistical analysis will be descriptive for plasma&#xD;
      concentrations with respect to time and the pharmacokinetic parameters of Cmax, Tmax, AUC0-t,&#xD;
      AUC0-inf, TMR, Ke, T1/2 of glimepiride and metformin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Predose,0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose</time_frame>
    <description>Cmax, Area Under Curve, Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose</time_frame>
    <description>Any change in health or undesirable experience in volunteers related or unrelated with the experimental drug.&#xD;
Adverse events were determined using clinical and laboratory test results, throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glimepiride / Extended release Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride / Extended release Metformin (4/850 mg).</intervention_name>
    <description>One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.</description>
    <arm_group_label>Glimepiride / Extended release Metformin</arm_group_label>
    <other_name>GLIMETXR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Mexican volunteers, considered healthy according to standard screening&#xD;
             assessments&#xD;
&#xD;
          -  Aged between 18 and 50 years old&#xD;
&#xD;
          -  Body mass index (BMI) was 18 to 27.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with a history or evidence of cardiovascular, renal, hepatic, gastrointestinal,&#xD;
             neurologic, muscular, metabolic, or hematologic abnormality&#xD;
&#xD;
          -  Any acute or chronic disease&#xD;
&#xD;
          -  Any drug allergy and female volunteers positive to urinary pregnancy test or&#xD;
             breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yamanqui Ibañez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>INVESTIGACIÓN FARMACOLÓGICA Y BIOFARMACEUTICA.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigacion Farmacologica Y Biofarmaceutica, S.A. de C.V.</name>
      <address>
        <city>México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W. Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):481-2.</citation>
    <PMID>1490793</PMID>
  </results_reference>
  <results_reference>
    <citation>Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996 Feb 29;334(9):574-9. Review.</citation>
    <PMID>8569826</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998 Oct;32(10):1044-52. Review.</citation>
    <PMID>9793597</PMID>
  </results_reference>
  <results_reference>
    <citation>Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan;102(1):99-110. Review.</citation>
    <PMID>9209206</PMID>
  </results_reference>
  <results_reference>
    <citation>DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999 Aug 17;131(4):281-303. Review.</citation>
    <PMID>10454950</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM2</keyword>
  <keyword>glimepiride</keyword>
  <keyword>metformin extended release</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

